A comparison and guidance for use of the principal stratum framework for COA endpoints Konstantina Skaltsa 1 , Paolo Eusebi 2 , Michael Schlichting 3 , Pavol Kral 4 1 IQVIA, Barcelona, Spain, 2 IQVIA, Rome, Italy, 3 Merck KGaA, Frankfurt, Germany, 4 IQVIA, Bratislava, Slovakia Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2033 Aims It is common for researchers to seek to understand the treatment effect of an intervention in certain subsets of participants of a clinical trial
Topics Discussed: What's the difference between microdosing and standard GLP1s
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-fl-naphthylamidE
Yes, it is necessary to have a local authorized representative (LAR) in Singapore for medical device registration